Rudy Joudet
Health summary
Rudy Joudet Male · DOB 11 Feb 1981 (45 y) · Blood type B+ · 5′11″ · 190 lb
Latest labs · 23 Jul 2026
Latest imaging · 7 Aug 2026
Whole-body MRI · 4 Mar 2026
ApoB
115
mg/dL · ref <90
up from 85 (Jun 24)
Vascular age
52
years · chrono 44/45
carotid IMT, Dec 25
Total testosterone
212
ng/dL · ref 250–1100
down from 363 (Mar 26)
FSH
26.4
mIU/mL · ref 1.4–12.8
pattern: primary
AHI
23.8
events/h · ref <5
moderate OSA, on OAT
Active concerns

Atherogenic lipids rising (ApoB 115, LDL-P 1943) · primary hypogonadism with severe oligospermia · moderate obstructive sleep apnoea · multilevel degenerative disc disease · vitamin D 26 · blood mercury 11 · slightly elevated lipase

01

Findings by status

Labs drawn 23 Jul 2026
Out of range · 13
ApoB
115
<90
LDL-P
1943
<1138
Vascular age
52
chrono 44/45
Total testosterone
212
250–1100
Free testosterone
42.6
46–224
FSH
26.4
1.4–12.8
DHEA-S
52
61–442
Sperm concentration
0.5
>15
Vitamin D
26
30–100
Mercury, blood
11
≤10
Sleep apnoea, AHI
23.8
<5
Degenerative disc diseaseL3–S1 · C5/C6 · L5/S1
MRI
GynecomastiaTeen onset
Mild
Monitor · 7
Lipase
64
12–53
Gallbladder polyp
6 mm
benign
Hepatic hemangioma
7 mm
benign
Hepatic cyst
8 mm
benign
Antral gastritis
EGD
mild
Chronic duodenitis
Marsh 0
not celiac
PVC burden
2.1%
<1%

Benign incidental findings, followed on serial imaging.

Within range · 17
Echo ejection fraction
55–60
≥55
Bruce protocol
12.1
≥10 METs
Lp(a)
<10
<75
hsCRP
0.7
<1
Triglycerides
91
<150
HbA1c
5.4
<5.7
Fasting glucose
97
65–99
Liver fibrosis
F0
Ultrasound
Whole-body MRI
Clear
no malignancy
OmegaCheck
7.9
≥5.4
eGFR
105
≥60
Cortisol, AM
11.9
4–22
Close-angle glaucoma
Treated
LPI
Ferritin
59
38–380
TSH
0.89
0.40–4.50
Homocysteine
10.5
≤13.5
SHBG
16
10–50
02

Cardiovascular

Jan 2023 – Jul 2026
ApoB
115
<90
LDL-C
136
<100
Non-HDL
156
<130
Total cholesterol
200
<200
HDL
45
≥40
Triglycerides
91
<150
LDL-P
1943
<1138
Small LDL-P
393
<142
Medium LDL-P
274
<215
Large HDL-P
4875
>6729
LDL peak size
210.6 Å
>222.9 Å
Lp(a)
<10
<75
hsCRP
0.7
<1
Vascular age
52
chrono 44/45
Carotid IMT
0.65 / 0.54
mm R/L
Echo EF
55–60
≥55
Bruce METs
12.1
≥10
PVC burden / IRBBB
2.1% / 118
QRS <120
03

Endocrine

Aug 2022 – Jul 2026 · no exogenous testosterone
Total testosterone
212
250–1100
Free testosterone
42.6
46–224
FSH
26.4
1.4–12.8
LH
7.1
1.5–9.3
SHBG
16
10–50
Estradiol
<30
≤39
Bioavailable testosterone
93.2
110–575
DHEA-S
52
61–442
Cortisol, AM
11.9
4–22
04

Fertility

10 semen analyses · Apr 2022 – Jul 2026
DateVol mLConc M/mLMotility %
8 Apr 222.01.556
18 May 228.01.118
31 Jan 232.0rare—
6 Feb 235.00.3<5
28 Mar 232.80.2—
4 May 243.30.560
22 May 245.50.922
26 Nov 25—0.146
28 Jan 26—0.000633
24 Jul 262.00.525

Reference concentration >15 M/mL. 22 May 24 drawn on anastrozole. Varicocele: faint on one ultrasound, not confirmed by two subsequent urologists.

05

Sleep

CPAP not tolerated · now oral appliance
Hoag home sleep test · May 2023
AHI 23.8
  • Type · HST
  • Nadir · 84%
  • ODI · 36.8
  • Time ≤88% · 5.9 min
Daybreak · night 1 · Nov 2025
RDI 13.6
  • Type · Mandibular advancement
  • Nadir · 91%
  • ODI · 2.7
  • Time ≤88% · —
Daybreak · night 2 · Nov 2025
RDI 2.8
  • Type · Mandibular advancement
  • Nadir · 89%
  • ODI · 0.6
  • Time ≤88% · —

Reference AHI/RDI <5 events per hour. CPAP ordered 2023, not tolerated; mandibular advancement device since Nov 2025.

06

Gastrointestinal & hepatobiliary

Serial imaging 2023 – Aug 2026
Lipase
64 U/L
  • Mar 25 · 72 U/L · LabCorp · in range · 13–78
  • Jul 26 · 65 U/L · Quest · high · 7–60
  • Aug 26 · 64 U/L · Germano de Sousa · high · 12–53
Hepatic steatosis
F0
  • Jan 23 · Ultrasound: fatty liver
  • Oct 23 · FibroScan F0 · 3.1 kPa · CAP 225
  • Mar 26 · Whole-body MRI: no fat, cysts to 10 mm
  • Mar 26 · Ultrasound: normal echogenicity
  • Aug 26 · Ultrasound (Affidea): minimal fat
Hemangioma + hepatic cyst
7 / 8 mm
  • Mar 25 · Ultrasound: 7 × 8 mm lesion
  • Mar 26 · 7 mm left-lobe mass, most likely hemangioma
  • Mar 26 · 8 mm simple right hepatic cyst
  • Aug 26 · ~7 mm, possible hemangioma · stable
Gallbladder polyp
6 mm
  • Jan 23 · 6 mm
  • Mar 25 · 7 × 7 × 6 mm
  • Mar 26 · 5 mm (MRI) · 5 mm (ultrasound)
  • Aug 26 · 6 mm · no cholelithiasis
07

Imaging & procedures

Whole-body MRI 4 Mar 2026 · rescan 24 mo
Prenuvo whole-body MRI

No malignancy

Oncologic
No evidence of malignancy
Spine
Disc disease at L3–S1, C5/C6, L5/S1
Abdo wall
Bilateral inguinal hernias; right 5 × 2.3 cm fat-containing
Chest
Mild gynecomastia, teen onset
Prostate
Volume 25.9 mL
Colon
Incidental diverticulosis; no diverticulitis
Knee
Baker cyst
Soft tissue
Prior liposuction scar
Follow-up
Weight 190 lb at scan · rescan advised at 24 months
Colonoscopy & EGD · 7 Apr 2025
Colonoscopy
4 mm distal sigmoid sessile polyp, cold snare
Histology
Tubular adenoma
Rectum
Mild internal hemorrhoids; otherwise normal to terminal ileum
EGD
Mild antral gastritis
Z-line
Irregular at 41 cm, biopsied — no Barrett’s, no metaplasia
H. pylori
Negative (biopsy + breath test 3 Feb 2026)
Duodenum
Mild chronic duodenitis, Marsh 0 — not celiac
Ophthalmology · Treated
2020
Close-angle glaucoma, first presentation right eye
Treatment
Both eyes: laser peripheral iridotomy + iridoplasty
08

Metabolic, renal & thyroid

23 Jul 2026
Vitamin D, 25-OH
26
30–100
Mercury, blood
11
≤10
Ferritin
59
38–380
Urine protein
Trace
negative
HbA1c
5.4
<5.7
Fasting glucose
97
65–99
Insulin
9.9
≤18.4
TSH
0.89
0.40–4.50
Free T4
1.3
0.8–1.8
Free T3
3.3
2.3–4.2
eGFR
105
≥60
PSA
0.4
0.0–4.0
PSA, % free
25
≥25
OmegaCheck
7.9
≥5.4
09

Medications & supplements

Current as of 16 Aug 2026
Prescribed
Retatrutide
0.5 mg weekly
Weight management
Tadalafil
5 mg daily
Vascular / longevity
Oral BPC-157 + KPV
500 + 500 mcg daily
Gastrointestinal
Supplements · 13
Vitamin D3
8,000 IU
Vitamin K2
200 mcg
NAC
600 mg
Zinc carnosine
75 mg ×2
Selenium
100 mcg
Magnesium glycinate
200 mg
Glycine
10 g
Psyllium
1 tbsp
Omega‑3
EPA 1,380 · DHA 520
Creatine
5 g
Spermidine
8 mg
NMN
500 mg
DHEA
25 mg
Rudy Joudet · confidential PHI · not medical advice